Defibrotide in recurrent thrombotic thrombocytopenic purpura

Clin Appl Thromb Hemost. 2000 Apr;6(2):69-70. doi: 10.1177/107602960000600203.

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a common illness characterized by platelet thrombi within the microvascularization. In its natural course, this disease has had a mortality rate of 90%. Plasma infusion or exchange achieved a survival rate of 70% to 90%. However, 10% to 30% of patients surviving the initial TTP episode relapse at regular intervals. The treatment of recurrent forms of the disease remains a challenge; several approaches have been shown to induce medium to long term remissions. We describe a patient with recurrent TTP whose disease remitted after administration of defibrotide.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Humans
  • Injections, Intravenous
  • Male
  • Plasma Exchange
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Count / drug effects
  • Polydeoxyribonucleotides / administration & dosage
  • Polydeoxyribonucleotides / therapeutic use*
  • Purpura, Thrombotic Thrombocytopenic / blood
  • Purpura, Thrombotic Thrombocytopenic / drug therapy*
  • Recurrence

Substances

  • Platelet Aggregation Inhibitors
  • Polydeoxyribonucleotides
  • defibrotide